Thermo Fisher Scientific issues conservative profit guidance, stock price declines

K-LinePoet · 2026-03-03T15:23:03+00:00

Thermo Fisher Scientific expects profits in 2026 to potentially fall below expectations, mainly due to U.S. government budget cuts affecting demand for scientific equipment, along with competitive pressures and challenges in the mid-to-low-end market. Although pharmaceutical demand has rebounded, demand for high-end instruments remains sluggish. The company is closing some factories to optimize efficiency, which may impact market confidence in the short term. Some institutions remain optimistic about its long-term prospects.

K-LinePoet

2026-03-03 15:23:03

Abstract generation in progress

Science and Technology Daily: Thermo Fisher Scientific explicitly stated in early February 2026 that its profit guidance for 2026 might be below Wall Street expectations. This cautious outlook is mainly based on the following objective factors:

Industry Policies and Environment

The company pointed out that U.S. government budget cuts for academic research institutions will continue into 2026, leading downstream research clients and biotech companies to adopt a more cautious approach to equipment procurement. The measures taken by the Trump administration to cut research funding directly impacted Thermo Fisher’s core customer base, thereby suppressing short-term demand. U.S. trade policies and rising supply chain costs between China and the U.S. have intensified competitive pressures, and some of the company’s low-margin businesses face fierce competition in the domestic mid-to-low-end market. Management emphasized in the financial report that these external challenges require a more cautious performance outlook.

Operational Conditions

Although demand from pharmaceutical clients rebounded significantly in Q4 2025, high-end instrument demand from U.S. government and academic clients remained sluggish due to budget constraints. The analytical instruments segment saw an 11.2% year-over-year profit decline in 2025, reflecting growth pressures in this area.

Company Status

The company recently announced the closure of factories in Franklin, Massachusetts, and Asheville, North Carolina, planned to be completed by the end of 2026. These adjustments aim to optimize global operational efficiency and focus resources on high-margin businesses, but may incur restructuring costs in the short term and impact market confidence.

Institutional Views

Some institutions, such as CMB International, still maintain a “Buy” rating, believing that long-term demand for biopharmaceuticals and strategic acquisitions will support competitiveness. However, the weak short-term guidance remains a primary concern.

The above content is compiled from public information and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.